The laboratory includes assessments at a systems-biology level from genomic, transcriptomic, proteomic and metabolomic assays through to focused assessment of candidate therapeutic vulnerabilities. It aligns with, and is informed by, discovery work performed through the Medical Genomics Division.
This enables forward and backward translation from pre-clinical and clinical discovery and the development of specific therapeutics, while seeking the evidence that supports efficacy and defining mechanisms of resistance.
The Laboratory has developed and accessed extensive next-generation model systems, including a large compendium of patient-derived cell lines that have been extensively characterised using multiple -omic approaches. This enables scientific enquiry to direct the trajectory of a precision oncology strategy, where candidate interventions are defined through a mechanistic understanding of specific segments of disease that differ based on molecular pathology.